In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum.
A direct study evaluating whether differential drug uptake of topical 2% miconazole and 2% ketoconazole from cream formulations into human stratum corneum correlated with differential pharmacological activity against Candida albicans was investigated in healthy human subjects. A single 24-h topical dose of 2% ketoconazole cream or 2% miconazole cream was applied unoccluded, at the same dose (2.6 mg of formulation per cm2 of surface area), at four skin sites on both ventral forearms of six human subjects. At the end of the treatment, residual drug was removed with a tissue from all sites and the treated site was tape stripped 11 times, either 1, 4, 8, or 24 h later. The first tape disc was discarded. The remaining tape discs, 2 through 11, were combined and extracted for drug quantification by high-performance liquid chromatography and bioactivity against C. albicans growth in vitro. Topical 2% ketoconazole produced 14-, 10-, and 7-fold greater drug concentrations in stratum corneum than 2% miconazole at 1, 4, and 8 h after a single topical dose. Ketoconazole and miconazole concentrations in the stratum corneum were similar 24 h after drug removal. Tape disc extracts from 2% ketoconazole-treated skin sites demonstrated significantly greater bioactivity in the bioassay than 2% miconazole. The increased efficacy of 2% ketoconazole compared with that of 2% miconazole in vitro reflects their differential uptake into the stratum corneum and inherent pharmacological activity. Tape stripping the drug-treated site in conjunction with a bioassay is therefore a useful approach in the determination of bioavailability of topical antifungal agents.
Pershing
L K
LK
Department of Medicine, University of Utah School of Medicine, Salt Lake City 84132.
Corlett
J
J
Jorgensen
C
C
D000287:Administration, Topical; D000328:Adult; D001682:Biological Availability; D002176:Candida albicans / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D008297:Male; D008825:Miconazole / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D012867:Skin / Q000737:chemistry; D012869:Skin Absorption
D008825:Miconazole; D007654:Ketoconazole